Loading clinical trials...
Loading clinical trials...
A Phase II, Prospective, Randomized, Double-masked, Parallel Group, Multi-center Study Assessing the Safety and Efficacy of 2% Rebamipide (OPC-12759) Compared to Placebo in Clearing of Fluorescein Staining of the Central Cornea in Subjects With Keratoconjunctivitis Sicca (Dry Eye)
Conditions
Interventions
rebamipide 2% ophthalmic suspension
placebo eye drops
Locations
19
United States
East Valley Ophthalmology
Mesa, Arizona, United States
Arizona Center for Clinical Trials, LLC
Phoenix, Arizona, United States
Cornea Consultants of Arizona
Phoenix, Arizona, United States
Macy Eye Center
Los Angeles, California, United States
Corneal Consultants of Colorado
Littleton, Colorado, United States
Specialty Eye Care
Parker, Colorado, United States
Start Date
February 1, 2010
Primary Completion Date
January 1, 2011
Completion Date
February 1, 2011
Last Updated
January 11, 2012
NCT07463950
NCT07363824
NCT07396441
NCT07298811
NCT07295691
NCT07191847
Lead Sponsor
Kubota Vision Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions